Autopsy report · NCT05288283
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
Cause of deathFunding or business
“The study was terminated due to a business decision.”
Life of this trial
- Registered 8 months before it started.
- Ran for about 11 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Jazz Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Seizures Associated With EMAS
- Interventions
- GWP42003-P; Placebo
- Participants
- 3
- Sites
- 14
- Countries
- Italy, United States
Trials that died the same way
- Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma
“The study was terminated from a business perspective.” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
“The study was terminated due to strategic business reasons.” - Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
“Study terminated due to business decision” - SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
“The study was terminated early due to company decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.